Kura Oncology reports 67% response rate in Phase 1 darlifarnib-adagrasib trial for KRAS G12C pancreatic cancer

Kura Oncology

Kura Oncology

KURA

0.00
  • Kura Oncology reported first-in-human Phase 1a FIT-001 data for darlifarnib with adagrasib in KRAS G12C-mutated solid tumors.
  • Results will be presented at ASCO on May 30, 2026.
  • The combination showed broad tumor reduction signals in heavily pretreated patients, including those previously treated with KRAS inhibitors.
  • Safety was described as manageable, supporting continued development as a combination partner for targeted therapies.
  • Kura will not advance the 8 mg darlifarnib dose in this combination for further evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260602PRIMZONEFULLFEED9726132) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.